

May 27, 2024

The Manager – Listing
BSE Limited,
1st Floor, New Trading Ring
Rotunda Building, P J Towers, Dalal Street, Fort,
Mumbai 400001

The Manager – Listing
National Stock Exchange of India Ltd.
Exchange Plaza, 5th Floor, Plot No. C/1, G Block
Bandra-Kurla Complex, Bandra (E),
Mumbai 400051

Dear Sirs,

Sub: Outcome of the Board Meeting held on Monday, May 27, 2024

Ref: Scrip Code - BSE: 506820 / NSE: ASTRAZEN

The Board of Directors of the Company at its meeting held today i.e., May 27, 2024, has *inter-alia*:

1. Approved the Audited financial results of the Company for the quarter and year ended March 31, 2024. The said Audited financial results together with the Audit report of the Statutory Auditors dated May 27, 2024 are enclosed herewith.
2. Recommended Dividend of Rs. 24/- per equity share for the financial year 2023-24.

We also confirm that the Statutory Auditor's Report is with unmodified opinion in respect of the Audited financial results of the Company for the financial year ended March 31, 2024.

The press release with regard to the same is also enclosed herewith.

The meeting commenced at 2:00 P.M. and concluded at 5:15 P.M. (IST).

Please take the same on record.

Thanking you,
Yours faithfully,

For **AstraZeneca Pharma India Limited**



Manasa. R
Company Secretary



Encl: As above

AstraZeneca Pharma India Limited
 Regd. Office : Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore 560 045
 Statement of financial results for the quarter and year ended 31 March 2024

| SI No. | Particulars | 'Rs in lakhs except for earnings per share data | | | | |
|-----------|---|---|---------------------------------------|---|--------------------------|--------------------------|
| | | 3 months ended 31/03/2024 | Previous 3 months ended 31/12/2023 | Corresponding 3 months ended in the previous year 31/03/2023 | Year ended 31/03/2024 | Year ended 31/03/2023 |
| | | Refer note 6 | Unaudited | Refer note 5 | Audited | Audited |
| 1 | Income | | | | | |
| | a) Revenue from operations | 38,319.88 | 30,578.90 | 28,470.35 | 129,552.82 | 100,297.08 |
| | b) Other income | 866.39 | 965.99 | 799.72 | 3,480.04 | 2,610.18 |
| | Total income | 39,186.27 | 31,544.89 | 29,270.07 | 133,032.86 | 102,907.26 |
| 2 | Expenses | | | | | |
| | (a) Cost of materials consumed | 3,361.71 | 3,751.88 | 2,161.98 | 12,901.55 | 8,437.84 |
| | (b) Purchase of stock-in-trade | 7,487.83 | 18,153.37 | 10,371.27 | 49,930.59 | 32,445.69 |
| | (c) Changes in inventories of finished goods, work-in-progress and stock-in-trade | 10,495.38 | (7,076.10) | (2,669.99) | (3,376.53) | (4,885.80) |
| | (d) Employee benefit expense | 5,797.88 | 6,323.36 | 6,685.98 | 24,145.32 | 25,910.26 |
| | (e) Depreciation expense | 376.41 | 370.46 | 424.89 | 1,494.05 | 1,626.00 |
| | (f) Allowance for expected credit loss (net) | 417.80 | (3.09) | 41.29 | 543.74 | 167.03 |
| | (g) Selling, marketing and distribution expense | 2,114.45 | 2,835.29 | 1,378.72 | 8,600.72 | 5,974.17 |
| | (h) Other expenses | 3,896.02 | 5,088.52 | 4,516.24 | 18,362.28 | 15,735.38 |
| | (i) Finance costs | (6.56) | 61.27 | 8.80 | 120.07 | 63.32 |
| | Total expenses | 33,760.92 | 29,504.96 | 22,919.18 | 112,721.79 | 86,473.89 |
| 3 | Profit before exceptional items and tax (1-2) | 5,435.35 | 2,039.93 | 6,360.89 | 20,310.87 | 17,433.37 |
| 4 | Exceptional items (expense) / income (Refer Note 4) | - | - | (4,022.91) | 1,642.63 | (4,022.91) |
| 5 | Profit before tax (3+4) | 5,435.35 | 2,039.93 | 2,337.98 | 21,963.50 | 13,410.46 |
| 6 | Tax expense | | | | | |
| | - Current tax | 1,551.52 | 465.34 | 638.18 | 5,355.00 | 3,830.25 |
| | - Tax expense for prior years (Refer Note 4a) | - | - | - | 537.95 | - |
| | - Deferred tax charge/ (credit) | (63.89) | (5.50) | (237.32) | (90.31) | (349.04) |
| | Total tax expense | 1,487.63 | 469.84 | 600.86 | 6,802.64 | 3,481.21 |
| 7 | Profit after tax (5-6) | 3,947.72 | 1,580.09 | 1,727.12 | 16,160.86 | 9,929.25 |
| 8 | Other comprehensive Income/(loss) | | | | | |
| | A. Items that will not be reclassified to profit or loss | | | | | |
| | Re-measurement gains/(losses) on post employment benefit obligations | 27.11 | 7.09 | (278.74) | 133.41 | (349.35) |
| | Income tax effect on above | (6.66) | (1.78) | 70.15 | (33.41) | 87.92 |
| | Other comprehensive Income/ (loss), net of income tax | 20.45 | 6.31 | (208.59) | 100.00 | (261.43) |
| | Total comprehensive income for the period (7+8) | 3,968.17 | 1,586.40 | 1,518.53 | 16,260.86 | 9,667.82 |
| 9 | Paid-up equity share capital (Face value of Rs 2/- per equity share) | 500.00 | 500.00 | 500.00 | 500.00 | 500.00 |
| 10 | Other Equity | - | - | - | 70,691.74 | 58,368.83 |
| 11 | Earnings per equity share of Rs 2/- each (basic and diluted) | 16.79 | 6.32 | 6.91 | 64.80 | 39.72 |

Amritha




AstraZeneca Pharma India Limited
Regd. Office : Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road,
Bangalore 560 045


Statement of financial results for the quarter and year ended 31 March 2024

Notes:

- 1 The Statements of Financial Results have been prepared in accordance with the applicable Indian Accounting Standards notified under Section 133 of the Companies Act, 2013 [Companies (Indian Accounting Standards) Rules, 2015 (as amended)] and other accounting principles generally accepted in India.
- 2 The Company has identified 'Healthcare Segment' as its only reportable segment in accordance with the requirements of Ind AS 108, 'Operating Segments'. Accordingly no segment information has been provided.
- 3 During the current year, the Company made an announcement to Stock exchanges on 16 November 2023 about its intention to exit the Company's manufacturing site in Bangalore in due course. The Company subsequently started exploring the option of sale of the manufacturing site in a fully operational manner to a Contract Manufacturing Organisation. The exploration process is currently ongoing and the exit will happen in due course which is estimated to take more than 12 months. Accordingly, the Company has concluded that there is no impact on the financial results for the quarter and year ended 31 March 2024.
- 4 **Exceptional items**
 - a The Company has entered into an Advance Pricing Agreement with Central Board of Direct Taxation for financial years 2015-2016 to 2019-2020 for which there were certain previously disclosed disputed Transfer Pricing matters consequent to which an amount of Rs.1,642.63 Lakhs is disclosed as an exceptional income for the year ended 31 March 2024.
 - b Exceptional items for the quarter and year ended 31 March 2023 consists of separation cost amounting to Rs. 1,910.32 Lakhs and Voluntary Retirement Scheme expenses amounting to Rs. 2,112.59 Lakhs.
- 5 The figures for the quarter ended 31 March 2024 and 31 March 2023 are the balancing figures between the audited figures in respect of the full financial years and the published unaudited year-to-date figures up to the third quarter of the respective financial years which were subjected to limited review by the statutory auditors.
- 6 The Board of Directors, at its meeting dated 27 May 2024, have recommended a final dividend of Rs. 24 per equity share aggregating to Rs. 6,000 Lakhs which is subject to approval of shareholders at the ensuing Annual General Meeting .
- 7 This Statement of financial results, Statement of assets and liabilities and Statement of cash flows were reviewed and recommended by the Audit Committee of the Board and subsequently approved by the Board of Directors at their respective meetings held on 27 May 2024.

Place: Bengaluru
Date: 27 May 2024

By Order of the Board of Directors
For AstraZeneca Pharma India Limited


Sanjeev Kumar Panchal
Managing Director



AstraZeneca Pharma India Limited
Regd Office : Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road,

Statement of assets and liabilities

(Rs. in lakhs)

| Sl.No. | Balance Sheet | As at | As at |
|--------|--|-------------------|------------------|
| | | 31 March 2024 | 31 March 2023 |
| | | Audited | Audited |
| | ASSETS | | |
| 1 | Non-current assets | | |
| | (a) Property, plant and equipment | 6,037.14 | 6,281.45 |
| | (b) Right-of-use assets | 420.00 | 604.93 |
| | (c) Capital work-in-progress | 27.06 | 133.02 |
| | (d) Intangible assets | 211.05 | - |
| | (e) Financial Assets | | |
| | (i) Loans | 27.38 | 87.78 |
| | (ii) Other financial assets | 246.76 | 309.52 |
| | (f) Current tax assets (net) (non-current) | 5,263.05 | 5,156.85 |
| | (g) Deferred tax assets (net) | 2,124.91 | 2,066.79 |
| | (h) Other non-current assets | 174.94 | 299.27 |
| | Sub-total - Non-current assets | 14,532.29 | 14,939.61 |
| 2 | Current assets | | |
| | (a) Inventories | 22,788.20 | 19,021.41 |
| | (b) Financial Assets | | |
| | (i) Trade receivables | 15,312.60 | 10,752.37 |
| | (ii) Cash and cash equivalents | 50,556.87 | 50,033.74 |
| | (iii) Bank balances other than cash and cash equivalents | 27.36 | 13.94 |
| | (iv) Loans | 12.59 | 7.93 |
| | (v) Other financial assets | 1,787.72 | 1,057.77 |
| | (c) Other current assets | 2,785.20 | 2,661.75 |
| | Sub-total - Current assets | 93,270.54 | 83,548.91 |
| | TOTAL - ASSETS | 107,802.83 | 98,488.52 |
| 1 | EQUITY AND LIABILITIES | | |
| | Equity | | |
| | (a) Equity Share capital | 500.00 | 500.00 |
| | (b) Other Equity | 70,691.74 | 58,368.83 |
| | Sub-total - Shareholders' funds | 71,191.74 | 58,868.83 |
| | LIABILITIES | | |
| | Non-current liabilities | | |
| | (a) Financial Liabilities | | |
| | (i) Lease liabilities | 278.36 | 369.11 |
| | (b) Provisions | 620.96 | 856.42 |
| | Sub-total - Non-current liabilities | 899.32 | 1,225.53 |
| 2 | Current liabilities | | |
| | (a) Financial Liabilities | | |
| | (i) Lease liabilities | 181.46 | 352.25 |
| | (ii) Trade payables | | |
| | Total outstanding dues of micro and small enterprises | 360.70 | 661.60 |
| | Total outstanding dues of creditors other than micro and small enterprises | 19,289.87 | 22,126.08 |
| | (iii) Other financial liabilities | 3,101.47 | 3,037.23 |
| | (b) Provisions | 4,341.53 | 4,168.43 |
| | (c) Current tax liabilities (net) | 666.10 | 242.29 |
| | (d) Other current liabilities | 7,770.64 | 7,806.28 |
| | Sub-total - Current liabilities | 35,711.77 | 38,394.16 |
| | TOTAL - EQUITY AND LIABILITIES | 107,802.83 | 98,488.52 |



AstraZeneca Pharma India Limited

Regd Office : Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road,
Bangalore 560 045

Statement of cash flows

| Particulars | (Rs in lakhs) | |
|---|--|--|
| | Year ended 31 March 2024 Audited | Year ended 31 March 2023 Audited |
| A) Cash flow from operating activities | | |
| Profit before tax | 21,953.50 | 13,410.46 |
| Non-cash adjustments for : | | |
| Depreciation and amortisation expense | 1,494.05 | 1,626.00 |
| (Profit) on sale of property, plant and equipment (net) | (3.15) | (248.98) |
| Impairment of Other assets | 123.70 | - |
| Bad debts written off | - | 2.71 |
| Provisions no longer required written back | (17.71) | - |
| Interest income on deposits carried at amortised cost | (3,257.24) | (2,311.72) |
| Employee stock compensation expense | 273.81 | 237.15 |
| Unrealised foreign exchange gain (net) | 15.38 | (14.55) |
| Allowance for expected credit loss (net) | 543.74 | 167.03 |
| Finance costs | 120.07 | 63.32 |
| Operating profit before working capital changes | 21,246.15 | 12,931.42 |
| Changes in working capital: | | |
| (Increase) / Decrease in trade receivables | (5,117.95) | (2,316.84) |
| (Increase) / Decrease in inventories | (3,766.79) | (4,999.48) |
| (Increase) / Decrease in loans | 55.64 | (45.86) |
| (Increase) / Decrease in other financial assets | (619.60) | 140.39 |
| (Increase) / Decrease in other assets | (124.13) | (787.19) |
| Increase / (Decrease) in trade payables | (3,136.67) | 3,744.03 |
| Increase / (Decrease) in provisions | 87.89 | (378.06) |
| Increase / (Decrease) in other financial liabilities | (159.83) | (1,522.49) |
| Increase / (Decrease) in other liabilities | (35.14) | 3,145.68 |
| Cash generated from operations | 8,429.57 | 9,911.60 |
| Income taxes paid (net of refund) | (5,643.34) | (4,081.79) |
| Net cash generated from operating activities (A) | 2,786.23 | 5,829.81 |
| B) Cash flows from investing activities | | |
| Interest income on bank deposits | 3,209.35 | 2,314.73 |
| Purchase of property, plant and equipment and intangible assets | (1,076.47) | (852.00) |
| Proceeds from sale of property, plant and equipment | 41.31 | 347.95 |
| Net cash generated from / (used in) investing activities (B) | 2,174.19 | 1,810.68 |
| C) Cash flows from financing activities | | |
| Principal repayment of lease liabilities | (385.54) | (385.12) |
| Interest paid on lease liabilities | (51.75) | (63.32) |
| Dividend paid | (4,000.00) | (2,000.00) |
| Net cash generated from/ (used in) financing activities (C) | (4,437.29) | (2,448.44) |
| D) Net increase/ (decrease) in cash and cash equivalents (A+B+C) | 523.13 | 5,192.05 |
| E) Cash and cash equivalents at the beginning of the year | 50,033.74 | 44,841.69 |
| F) Cash and cash equivalents at the end of the year (D+E) | 50,556.87 | 50,033.74 |

[Handwritten Signature]



Price Waterhouse & Co Chartered Accountants LLP

INDEPENDENT AUDITOR'S REPORT

To the Board of Directors of AstraZeneca Pharma India Limited

Report on the Audit of Financial Results

Opinion

1. We have audited the annual financial results of AstraZeneca Pharma India Limited (hereinafter referred to as the "Company") for the year ended March 31, 2024 and the Statement of assets and liabilities and the Statement of cash flows as at and for the year ended on that date, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the 'Listing Regulations') which has been initialled by us for identification purposes.
2. In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial results:
 - (i) are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
 - (ii) give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards prescribed under Section 133 of the Companies Act, 2013 (the "Act") and other accounting principles generally accepted in India, of net profit and other comprehensive income and other financial information of the Company for the year ended March 31, 2024 and the Statement of assets and liabilities and the Statement of cash flows as at and for the year ended on that date.

Basis for Opinion

3. We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Act and other applicable authoritative pronouncements issued by the Institute of Chartered Accountants of India. Our responsibilities under those Standards are further described in the 'Auditor's Responsibilities for the Audit of the Financial Results' section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion.



Board of Directors' Responsibilities for the Financial Results

Price Waterhouse & Co Chartered Accountants LLP, 5th Floor, Tower 'D', The Millenia, 1 & 2 Murphy Road, Ulsoor Bengaluru - 560 008

T: +91 (80) 4079 5000, F: +91 (80) 4079 5222

Registered office and Head office: Plot No. 56 & 57, Block DN, Sector-V, Salt Lake, Kolkata - 700 091

Price Waterhouse & Co. (a Partnership Firm) converted into Price Waterhouse & Co Chartered Accountants LLP (a Limited Liability Partnership with LLP Identity no: LLPIN AAC-4362) with effect from July 7, 2014. Post its conversion to Price Waterhouse & Co Chartered Accountants LLP, its ICAI registration number is 304026E/E300009 (ICAI registration number before conversion was 304026E)

Price Waterhouse & Co Chartered Accountants LLP

INDEPENDENT AUDITOR'S REPORT

To the Board of Directors of AstraZeneca Pharma India Limited

Report on the Financial Results

Page 2 of 4

4. These financial results have been prepared on the basis of the annual financial statements. The Company's Board of Directors are responsible for the preparation and presentation of these financial results that give a true and fair view of the net profit and other comprehensive income and other financial information of the Company and the statement of assets and liabilities and the statement of cash flows in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Board of Directors of the Company are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the financial results by the Directors of the Company, as aforesaid.
5. In preparing the financial results, the Board of Directors of the Company are responsible for assessing the ability of the Company to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.
6. The Board of Directors of the Company are responsible for overseeing the financial reporting process of the Company.

Auditor's Responsibilities for the Audit of the Financial Results

7. Our objectives are to obtain reasonable assurance about whether the financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial results.



Price Waterhouse & Co Chartered Accountants LLP

INDEPENDENT AUDITOR'S REPORT

To the Board of Directors of AstraZeneca Pharma India Limited

Report on the Financial Results

Page 3 of 4

8. As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:
- (a) Identify and assess the risks of material misstatement of the financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
 - (b) Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls. (Refer paragraph 11 below)
 - (c) Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
 - (d) Conclude on the appropriateness of the Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Company to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
 - (e) Evaluate the overall presentation, structure and content of the financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.
9. We communicate with those charged with governance of the Company regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit. We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.



Price Waterhouse & Co Chartered Accountants LLP

INDEPENDENT AUDITOR'S REPORT

To the Board of Directors of AstraZeneca Pharma India Limited
Report on the Financial Results

Page 4 of 4

Other Matters

10. The Financial Results include the results for the quarter ended March 31, 2024, being the balancing figures between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year, which were subject to limited review by us. The Financial results for the quarter ended March 31, 2024 are neither subject to limited review nor audited by us.
11. The annual financial results dealt with by this report has been prepared for the express purpose of filing with the stock exchanges on which the Company's shares are listed. These results are based on and should be read with the audited financial statements of the Company for the year ended March 31, 2024 on which we issued an unmodified audit opinion vide our report dated May 27, 2024.

For Price Waterhouse & Co Chartered Accountants LLP
Firm Registration Number: 304026E/ E-300009



Sharmila Ramaswamy
Partner

Membership Number: 215131
UDIN: 24215131BKGSLU9136

Place: Bengaluru
Date: May 27, 2024

Press Release

AstraZeneca Pharma India Limited achieves growth of 29% for financial year ended March 31, 2024

Bangalore, May 27, 2024: AstraZeneca Pharma India Ltd., a science-led biopharmaceutical company, is pleased to announce robust financial results for the financial year ended March 31, 2024. The Company achieved total revenue of INR 1,330 Cr. registering an impressive 29% growth in revenue.

Financial performance highlights for full year 2023 - 24

- **Revenue from Operation** for financial year 2023-24 stood at INR 1,296 Cr. with substantial 29% increase.
- **Profit Before Tax** is INR 220 Cr. registering a commendable 64% growth (PBT before exceptional items at INR 201 Cr., up by 17% compared to previous financial year).
- **Earnings Per Share (EPS)** for financial year stood at INR 64.6 demonstrating a significant growth of 63%

The Board of Directors, at its meeting dated May 27, 2024, have recommended a final dividend of Rs. 24 per equity share for the financial year 2023-24, subject to approval of shareholders at the Annual General Meeting of the Company.

AstraZeneca India continues to advance its mission of transforming the future of healthcare by unlocking the power of science for the benefit of people, society, and the planet. The Company's commitment to innovation is reflected in its strong pipeline progress, reinforcing its position as a key player in the healthcare industry.

AstraZeneca globally announced its new Bold Ambition during the recently held Investor's Day, setting the stage for 2030 to deliver \$80 billion in Total Revenue. This will be achieved through significant growth in its existing oncology, biopharmaceuticals and rare disease portfolio, and by launching an expected 20 new medicines before the end of the decade, achieve industry leading growth and aim to be carbon negative.

Dr. Sanjeev Panchal, Country President and Managing Director, AstraZeneca India, commented, " FY 2023-24 was one of the strongest years for us in the country and we take immense pride in our consistent performance. AstraZeneca India products sales for first time cross INR 1000 Cr mark, delivering total revenue of almost INR ~1300 Cr. with growth of 29% this year. A successful execution of our growth through innovation strategy is helping us propel our ambition to be pioneers in science and lead in specialist disease areas in India. Science is guiding us, and our remarkable pipeline progress with 9 new medicines and indication approvals that we received last year, positions us optimally and we feel motivated to bring more innovative therapies faster and closer to patients in India.

Our scientific progress and great support from different states, peers, and industry stakeholders positions us optimally to achieve our purpose of leaving no patients behind in the therapy areas we are present in and sustainably continue our strive to contribute to people, society, and the planet."

Bhavana Agrawal, Chief Finance Officer, added, "Our strong full year performance is reflection of company's focus on being a specialist organization & strong operational execution. This achievement reflects our relentless pursuit of identifying and capitalizing on opportunities in a dynamic

environment. It underscores our dedication to not only achieving financial excellence but doing so in a sustainable and strategic manner."

AstraZeneca India remains committed to driving positive impact through groundbreaking scientific advancements and looks forward to contributing to the well-being of communities.

Key milestones achieved for full year 2023 - 24:

Marketing approvals for new molecules & indications:

- **Trastuzumab deruxtecan:** dual indication for treatment of HER2 low breast cancer and HER2 positive gastric / gastro-oesophageal cancer
- **Andexanet Alfa:** *for critical bleeding conditions associated with use of novel anticoagulants (Factor Xa inhibitors viz. Apixaban, rivaroxaban)*
- **Triple combination- budesonide (160 mcg), glycopyrrolate (7.2 mcg), and formoterol fumarate (5 mcg) dihydrate,** *pressurised inhalation, suspension for the effective maintenance treatment and maintenance to relieve symptoms and prevent exacerbations in adult patients with chronic obstructive pulmonary (COPD) disease*
- **Palivizumab:** *preventive therapy for Respiratory Syncytial Virus (RSV)*
- **Dapagliflozin:** *additional indication approval for treatment of heart failure in adults*
- **Tremelimumab in combination with Durvalumab:** *for the treatment of patients with unresectable hepatocellular carcinoma (uHCC)*
- **Trastuzumab deruxtecan:** *for the treatment of select HER-2 positive breast cancer, subsequently launched in January 2024*
- **Selumetinib:** *Entry into rare disease therapy in India for treatment of Neurofibromatosis type 1 (NF1) and who have symptomatic, inoperable plexiform neurofibromas (PN)*

Strategic collaborations with:

- **Government of Karnataka,** National Health Mission, Health & Family Welfare Services, to deploy Qure.ai's Artificial Intelligence (AI) based Lung Cancer screening technology. This cutting-edge technology can screen a patient for 29 lung diseases in a single chest X-ray, enhancing diagnostic capabilities.
- **Government of Goa** to accelerate the detection of lung cancer through the deployment of state-of-the-art Artificial Intelligence (AI) based screening technology developed by Qure.ai.
- Roche Diagnostics India, focusing on improving diagnostics for breast cancer patients. The collaboration aims to streamline HER2 diagnostics with the latest advancements in the field.
- **Rajiv Gandhi Cancer Institute and Research Center (RGC&RC),** Delhi to set up a Center of Excellence (CoE) to enhance the availability of subsidized, high-quality, and validated NGS (Next-Generation Sequencing) molecular panel testing for eligible individuals diagnosed with lung cancer in India.
- Inaugurated a dedicated CoEs for severe asthma at **Manipal Hospital, Goa; and Brahma Kumaris Hospita, Mumbai.** This facility plays a pivotal role in treating and managing severe asthma patients and serves as a guiding force for evolving severe asthma centers.
- **Mankind Pharma Limited** for exclusive distribution of AstraZeneca's budesonide and formoterol fumarate dihydrate (inhaled corticosteroid (ICS) and long-acting beta-agonist (LABA) combination) brand Symbicort in India. AstraZeneca will retain the intellectual property rights to budesonide and formoterol fumarate dihydrate and will continue to be the Marketing Authorisation Holder (MAH) and import license.

Sustainability & community highlights:

- Launched the **global AZ Forest program in India**, aiming to plant and maintain an estimated 64 million plants and trees in Meghalaya. Collaborated with Earthbanc, Earthtree, Worldview Impact (India), and Hill Farmers Shiitake Mushroom Coop Society on the 'Meghalaya Reforestation and Sustainable Livelihoods Project' (Regeneration Meghalaya), a 30-year initiative in northeast India.
- **Ganga Godavari Cancer Screening Program** dedicated to creating cancer awareness and early detection of oral, breast, and cervical cancers among women. We have screened over 10,000 women across 125+ camps in Delhi, Nasik, and Patna through specialized screening camps and community mobilization. Collaborating with state governments, Mohalla Clinics, the National Association for Reproductive and Child Health of India for PNP, and local government hospitals such as Lady Hardinge, Dr. B.R. Ambedkar Hospitals, SMBT Hospital, and Mahavir Cancer Sansthan, we aim to make a significant impact on women's health.
- **Young Health Program** focused on building knowledge and capacity among young people to limit risk behaviors and promote long-term health, this program has reached over 95,000 youth through 43 community activities. We have trained 145 youth as peer educators and 75 healthcare workers, engaging 28 government stakeholders to ensure a broader impact on youth health education.

Recognitions:

- **The Economic Times Best Healthcare Brands Award 2023** for growth, excellence and a commitment to innovation in sector
- **AsiaOne G20 Healthcare Commitment Award** for our commitment to the healthcare and well-being
- **Avtar Most Inclusive Companies Index (MICI): Best Companies for Women** for six consecutive years
- **Great Place To Work® Certification™**: Recognised for six consecutive years
- **Sustainability Initiative Award of the Year** for our zero-carbon ambition and industry leading initiatives by UBS Forums
- **ESG Champions of India 2024** in Biotechnology & Pharmaceuticals by Dun & Bradstreet India
- **Dr. Sanjeev Panchal**: Recognized among India's Impactful CEOs by Times Now for outstanding leadership.
- **Amarpreet Kaur Ahuja**, Country HR Director- India
 - Awarded the Diversity & Inclusion HR Leader of the Year 2023 by Ask Insights & TOI, showcasing excellence in fostering diversity and inclusion.
 - Featured among the most influential woman in HR-2024 by BW People

AstraZeneca India continues to make significant strides, demonstrating a commitment to innovation, healthcare advancements, environmental sustainability, and leadership excellence.

About AstraZeneca:

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in four therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory and Rare Diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Established in 1979, it is headquartered at Bengaluru, Karnataka and has a workforce of over 900 employees across the country committed to deliver great medicines to patients through innovative science and global excellence in development and commercialization. For more information, please visit our website: www.astrazeneca.com/india, or connect with us on [LinkedIn](#) and [X.com](#).